Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Published byDominick Nickolas Harper Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration."— Presentation transcript:

1 Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors.
mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. B16-F10.9-OVA-CD155 tumors were implanted subcutaneously, and when the tumor volume reached ~100 mm3, they were injected with DMEM (control) or mRIPO. Tumors were harvested after injection as indicated, digested to single-cell suspensions, and analyzed by flow cytometry. (A) Analysis of the percentage of CD45.2+ immune cells in the tumor after DMEM (control) or mRIPO treatment. Each bar represents three mice analyzed individually. (B) Cytokine concentrations in tumor homogenates. (C to E) Analysis of tumor-infiltrating neutrophils (C), DCs (D), and T cells (E) at the indicated days after mRIPO injection. (F) Longitudinal analysis of neutrophil, DC, CD4 T cell, and CD8 T cell infiltration is depicted as a percentage of total live cells in the tumor. Each bar represents three mice analyzed individually. Error bars represent SEM. The flow cytometry gating strategy is shown in figs. S9 and S10. Michael C. Brown et al., Sci Transl Med 2017;9:eaan4220 Published by AAAS

Download ppt "Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration."

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Synergistic antitumor effect of anti-CD40/CpG and 14
Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.
Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.

Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 5 A competent Fc is required for the antitumor immune response.
Immunologic responses after the MN-mediated cancer immunotherapy.

Immunologic responses after the MN-mediated cancer immunotherapy.
LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.

Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Similar presentations

Ads by Google